Navigation Links
Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors
Date:6/5/2010

Women facing breast cancer surgery can now be certain that a less-invasive technique called sentinel node resection is just as safe and effective as the traditional surgery of removing all lymph nodes from the underarm area, according to a new study being presented today at the American Society of Clinical Oncology (ASCO) meeting by oncologists from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh.

Chicago, IL (Vocus) June 5, 2010 -- Women facing breast cancer surgery can now be certain that a less-invasive technique called sentinel node resection is just as safe and effective as the traditional surgery of removing all lymph nodes from the underarm area, according to a new study being presented today at the American Society of Clinical Oncology (ASCO) meeting by oncologists from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh.

The study represents the first long-term comparison of the two methods’ effect on breast cancer survival and recurrence, said Thomas B. Julian, MD, Associate Director of the Breast Care Center at AGH and one of the clinical trial’s principal investigators, along with Norman Wolmark, MD, who serves as Chair of both the NSABP and the Department of Human Oncology at AGH.

The study, which enrolled 5,611 women over a period of five years, showed no significant difference in overall survival, disease-free survival, or regional control of cancer between the sentinel node resection alone versus complete axillary dissection of the lymph nodes.

“Sentinel node resection is now clearly the standard of care for women with clinically node-negative breast cancer, which comprise the majority of patients,” Dr. Julian said. “Many women with this disease are now able to avoid the potential complications of full lymph node removal and know that their cancer is being effectively treated.”

Removing all lymph nodes from the underarm area carries the risk of difficult and sometimes permanent complications ,including lost sensation in the back of the arm, tingling, weakness and swelling (lymphedema).

Sentinel nodes are normally the first lymph nodes to receive drainage as well as cancer cells from the breast tumor. Doctors can find the sentinel nodes and remove them with a small surgical procedure. If no cancer is found, removal of the remaining lymph nodes is not necessary.

The NSAPB study was the largest prospective randomized Phase III trial designed to determine that sentinel node resection alone results in the same survival and regional control as axillary dissection.

Participants across North America and Puerto Rico were randomly assigned to undergo either a sentinel node resection with an axillary dissection, or to a sentinel node biopsy alone followed by axillary dissection if a sentinel node biopsy showed cancer.

Overall eight–year survival was 91.8 percent for the sentinel node-alone patients and 90.3 percent for those who also had an axillary dissection. Disease-free survival rates were 82.4 percent for the sentinel node group and 81.5 percent for the axillary group. Local and regional recurrence of cancer happened 61 times in the sentinel node group and 63 times in the axillary group.

“These results validate sentinel node resection as a safe and effective treatment for node-negative breast cancer patients,” Dr. Julian said.

###

Read the full story at http://www.prweb.com/releases/breast_cancer_surgery/sentinel_node_resection/prweb4094574.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. News brief: Contrast agent with MRI improves detection of lymph nodes metastases
2. Vitamin D Linked to Survival in Lymphoma Patients
3. A new target for lymphoma therapy
4. The Leukemia & Lymphoma Society Available to Comment on Findings Presented at American Society of Hematology Conference
5. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
6. Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkins Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data
7. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
8. Tumors hide out from the immune system by mimicking lymph nodes
9. Specific lymph node radiotherapy is well tolerated after surgery in early breast cancer patients
10. New class of drug kills lymphoma cells
11. Routine breast cancer biopsy might predict lymph node cancer spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 2017 , ... Elisabete Miranda, president and CEO of ... magazine as one of its 2017 Enterprising Women of the Year, a prestigious ... that they have fast-growth businesses, mentor or actively support other women and girls ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. ... Pro . This new addition to the Mirroring360 product family combines device screen ... , Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from ... performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, and ... important patterns in student test score performance, the report’s limited analyses fail to ...
(Date:4/25/2017)... RESTON, VIRGINIA (PRWEB) , ... April 25, 2017 ... ... scientists leading the way in unveiling cutting-edge birth defects research related to Zika ... recognized by the world’s premier society for this important science. , ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), By ... 2014 - 2025" report to their offering. ... The Latin American pharmaceutical contract ... by 2025 Low drug registration cost in Latin ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
Breaking Medicine Technology: